NSE · MANGALAM
Mangalam Drugs and Organics Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹67 Cr with net profit ₹-13 Cr — a -19.41% net margin, versus -16.75% the period before.
Shareholding
As of 2026-06-30
- Promoter35.65%
- Public64.24%
- FII0.11%
- DII0%
24,465 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 4.08× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #81 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 38.42 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 70.26 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,235 Cr | 344.55 | 18.14 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Mangalam Drugs and Organics Ltd.(this company) | ₹43 Cr | 17.46 | 0.42 | -0.43% | -19.13% |
AI analysis
AI-generated · google/gemini-2.5-flashMangalam Drugs and Organics Ltd. has a market capitalization of Rs 43 Cr. The company reported revenue of Rs 318.73 Cr, representing a revenue growth of -13.7%. The profit margin for the company is -19.13%. The 52-week high for the share price was Rs 95, and the 52-week low was Rs 22.8.
Positives
- +The company has no pledged promoter shares, with promoter pledge at 0% as of June 30, 2026.
Negatives
- −Revenue declined by -13.7%.
- −The company reported a negative profit margin of -19.13%.
- −Return on Equity (ROE) is significantly negative at -43.08%.
- −Return on Capital Employed (ROCE) is negative at -15.4031%.
- −Promoter shareholding has decreased from 50.41% in Sept 2017 to 35.6516% in Jun 2026.
- −Quarterly net profits have been consistently negative; for instance, -13.42 Cr in Mar 2026.
Financial Performance
Mangalam Drugs and Organics Ltd. reported a revenue of Rs 318.73 Cr, which represents a decline of -13.7%. The company posted a negative profit margin of -19.13%. For the quarter ending Mar 2026, revenue was Rs 67.29 Cr with a net profit of -13.42 Cr. This follows a trend of negative net profits in previous quarters, including -9.84 Cr in Dec 2025 and -7.35 Cr in Sept 2025.
Profitability & Returns
The company's profitability metrics indicate negative returns. The Return on Equity (ROE) stands at -43.08%, and Return on Capital Employed (ROCE) is -15.4031%. The profit margin for the company is -19.13%. Earnings per share (EPS) is 0.
Balance Sheet
Mangalam Drugs and Organics Ltd. has a debt-to-equity ratio of 0.73. The book value per share is Rs 60.64. The company has no reported dividend yield.
Ownership & Pledges
Promoter holding in Mangalam Drugs and Organics Ltd. is 35.6516% as of June 30, 2026. There are no promoter shares pledged. The total number of shareholders is 24465.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Mangalam Drugs and Organics Ltd.share price & fundamentals